28 related articles for article (PubMed ID: 38501542)
1. Metabolic regulator LKB1 controls adipose tissue ILC2 PD-1 expression and mitochondrial homeostasis to prevent insulin resistance.
Sun J; Zhang Y; Zhang Q; Hu L; Zhao L; Wang H; Yuan Y; Niu H; Wang D; Zhang H; Liu J; Feng X; Su X; Qiu J; Sun J; Xu H; Zhang C; Wang K; Bi Y; Engleman EG; Shen L
Immunity; 2024 May; ():. PubMed ID: 38772366
[TBL] [Abstract][Full Text] [Related]
2. Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.
Zhao N; Zhu W; Wang J; Liu W; Kang L; Yu R; Liu B
Int Immunopharmacol; 2021 Oct; 99():107924. PubMed ID: 34217145
[TBL] [Abstract][Full Text] [Related]
3. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S; Chevalier MF; Martinez-Usatorre A; Gomez-Cadena A; Salomé B; Lecciso M; Salvestrini V; Verdeil G; Racle J; Papayannidis C; Morita H; Pizzitola I; Grandclément C; Bohner P; Bruni E; Girotra M; Pallavi R; Falvo P; Leibundgut EO; Baerlocher GM; Carlo-Stella C; Taurino D; Santoro A; Spinelli O; Rambaldi A; Giarin E; Basso G; Tresoldi C; Ciceri F; Gfeller D; Akdis CA; Mazzarella L; Minucci S; Pelicci PG; Marcenaro E; McKenzie ANJ; Vanhecke D; Coukos G; Mavilio D; Curti A; Derré L; Jandus C
Nat Commun; 2017 Sep; 8(1):593. PubMed ID: 28928446
[TBL] [Abstract][Full Text] [Related]
4. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for
Jou E; Rodriguez-Rodriguez N; Ferreira AF; Jolin HE; Clark PA; Sawmynaden K; Ko M; Murphy JE; Mannion J; Ward C; Matthews DJ; Buczacki SJA; McKenzie ANJ
Sci Immunol; 2022 Jun; 7(72):eabn0175. PubMed ID: 35658010
[TBL] [Abstract][Full Text] [Related]
5. The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients.
Zhang M; Wan Y; Han J; Li J; Gong H; Mu X
PeerJ; 2024; 12():e16988. PubMed ID: 38560459
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
7. Obesity correlates with the immunosuppressive ILC2s-MDSCs axis in advanced breast cancer.
Liu W; Li B; Liu D; Zhao B; Sun G; Ding J
Immun Inflamm Dis; 2024 Mar; 12(3):e1196. PubMed ID: 38501542
[TBL] [Abstract][Full Text] [Related]
8. Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
Jachetti E; Sangaletti S; Chiodoni C; Ferrara R; Colombo MP
Cell Immunol; 2021 Apr; 362():104301. PubMed ID: 33588246
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
10. Group 2 innate lymphoid cells (ILC2s): The spotlight in asthma pathogenesis and lung tissue injury.
Sadik S; Lu Y; Zhu S; Cai J; Mi LL
Allergol Immunopathol (Madr); 2021; 49(2):208-216. PubMed ID: 33641310
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of Group 2 Innate Lymphoid Cells Defines Their Pleiotropic Roles in Cancer, Obesity, and Cardiovascular Diseases.
Ikutani M; Nakae S
Front Immunol; 2022; 13():939378. PubMed ID: 35844571
[TBL] [Abstract][Full Text] [Related]
12. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target.
Jin J; Sunusi S; Lu H
J Int Med Res; 2022 Jan; 50(1):3000605211053156. PubMed ID: 35048721
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
